Valuation: CSL Limited

Market Cap 61.44B 54.87B 51.04B 46.43B 87.66B 5,946B 88.04B 614B 241B 3,032B 231B 226B 9,728B P/E 2027 *
21.2x
P/E 2028 * 19.2x
Enterprise Value 70.67B 63.12B 58.72B 53.41B 101B 6,840B 101B 707B 277B 3,487B 265B 260B 11,190B EV / Sales 2027 *
4.49x
EV / Sales 2028 * 4.31x
Free-Float
99.97%
Yield 2027 *
2.34%
Yield 2028 * 2.48%
1 day+2.17%
1 week+5.47%
Current month+0.85%
1 month+3.90%
3 months+46.74%
6 months+28.94%
Current year+11.84%
1 week 30.73
Extreme 30.73
32.29
1 month 29.49
Extreme 29.492
32.48
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
36.28
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%+5.47% - - 61.44B
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.56%+2.53%+28.57%+59.82% 422.63B
Weighted average by Cap. +1.21%+2.44%+31.57%+69.97%

Financials

2027 *2028 *
Net sales 15.76B 14.07B 13.09B 11.91B 22.48B 1,525B 22.58B 158B 61.73B 777B 59.17B 57.88B 2,495B 16.32B 14.57B 13.56B 12.33B 23.28B 1,579B 23.38B 163B 63.92B 805B 61.27B 59.93B 2,583B
Net income 2.82B 2.52B 2.34B 2.13B 4.03B 273B 4.04B 28.21B 11.05B 139B 10.6B 10.36B 447B 3.15B 2.81B 2.62B 2.38B 4.49B 305B 4.51B 31.49B 12.34B 155B 11.82B 11.57B 499B
Net Debt 9.23B 8.25B 7.67B 6.98B 13.17B 894B 13.23B 92.32B 36.17B 456B 34.67B 33.91B 1,462B 8.92B 7.97B 7.41B 6.74B 12.73B 863B 12.78B 89.19B 34.95B 440B 33.49B 32.76B 1,412B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
09/10/26 $32.21 +2.17% 46,351
08/10/26 $31.53 +0.05% 86,219
07/10/26 $31.51 +1.09% 65,057
06/10/26 $31.17 +0.81% 48,610
05/10/26 $30.92 +1.24% 52,100
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
128.29USD
Average target price
129.01USD
Spread / Average Target
+0.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited